Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback